An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
37783650
DOI
10.1016/j.schres.2023.09.002
PII: S0920-9964(23)00312-2
Knihovny.cz E-zdroje
- Klíčová slova
- Clozapine/administration and dosage, Clozapine/adverse effects, Clozapine/therapeutic use, Drug labeling, Europe, Eastern, Schizophrenia,
- MeSH
- antipsychotika * škodlivé účinky MeSH
- databáze faktografické MeSH
- farmakovigilance * MeSH
- klozapin * škodlivé účinky MeSH
- lidé MeSH
- nežádoucí účinky léčiv epidemiologie MeSH
- schizofrenie farmakoterapie MeSH
- systémy pro sběr zpráv o nežádoucích účincích léků statistika a číselné údaje MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- východní Evropa epidemiologie MeSH
- Názvy látek
- antipsychotika * MeSH
- klozapin * MeSH
OBJECTIVES: To compare the prevalence, regulations, and pharmacovigilance practices of clozapine use in Eastern European countries (except Russia). METHODS: Questionnaires and data from administrative databases (2016 and 2021), package inserts and national guidelines were collected from 21 co-authors from 21 countries. Reports of clozapine adverse drug reactions (ADRs) sent to the global pharmacovigilance database (VigiBase™) were analyzed from introduction to December 31, 2022. RESULTS: Clozapine prescription among antipsychotics in 2021 varied six-fold across countries, from 2.8 % in the Czech Republic to 15.8 % in Montenegro. The utilization of antipsychotics in both 2016 and 2021 was highest in Croatia, and lowest in Serbia in 2016, and Montenegro in 2021, which had half the defined daily dose (DDD)/1000/day compared to the Croatian data. From 2016 to 2021, the prevalence of antipsychotic use increased in almost all countries; the proportion of clozapine use mainly remained unchanged. Differences were detected in hematological monitoring requirements and clozapine approved indications. Only a few national schizophrenia guidelines mention clozapine-induced myocarditis or individual titration schemes. The VigiBase search indicated major underreporting regarding clozapine and its fatal outcomes. By comparison, the United Kingdom had less than half the population of these Eastern European countries but reported to VigiBase more clozapine ADRs by 89-fold and clozapine fatal outcomes by almost 300-fold. CONCLUSION: Clozapine is under-utilized in Eastern European countries. Introducing individualized clozapine treatment schedules may help to maximize clozapine benefits and safety. Major improvement is needed in reporting clozapine ADRs and fatal outcomes in Eastern European countries.
County Hospital Dr Fra Mihovil Sučić Livno Svetog Ive 2 Livno 80101 Bosnia and Herzegovina
Department of Psychiatry and Medical Psychology Belarusian State Medical University Minsk Belarus
Department of Psychiatry Medical University of Gdańsk Gdańsk Poland
Department of Psychiatry University Medical Centre Maribor Maribor Slovenia
National Institute of Mental Health Neurology and Neurosurgery Budapest Hungary
State University of Medicine and Pharmacy Nicolae Testemitanu Chişinău Republic of Moldova
Tbilisi State Medical University Department of Psychiatry Tbilisi Georgia
University Hospital Center Mother Teresa Tirana Albania
University of Kragujevac Faculty of Medical Sciences Department of Psychiatry Kragujevac Serbia
Citace poskytuje Crossref.org